Entering text into the input field will update the search result below

Xenon Pharmaceuticals, Inc. (XENE) CEO Simon Pimstone on Q4 2019 Results - Earnings Call Transcript

Mar. 09, 2020 10:28 PM ETXenon Pharmaceuticals Inc. (XENE)
SA Transcripts profile picture
SA Transcripts

Xenon Pharmaceuticals, Inc. (NASDAQ:XENE) Q4 2019 Earnings Conference Call March 9, 2020 4:30 PM ET

Company Participants

Jodi Regts - VP, Corporate Affairs & IR

Simon Pimstone - CEO & Director

Ian Mortimer - President, CFO, COO & Company Secretary

Conference Call Participants

Paul Matteis - Stifel, Nicolaus & Company

Lachlan Hanbury-Brown - William Blair & Company

Yatin Suneja - Guggenheim Securities

Maurice Raycroft - Jefferies


Ladies and gentlemen, thank you for standing by, and welcome to the Xenon Pharmaceuticals 2019 Financial Results Earnings Call. [Operator Instructions]. As a reminder, today's program is being recorded. I would now like to introduce your host for today's program, Jodi Regts. Please go ahead.

Jodi Regts

Thank you. Good afternoon. Thanks for joining us on our call and webcast to discuss our 2019 financial and operating results. Joining me on today's call are Dr. Simon Pimstone, Xenon's Chief Executive Officer; and Ian Mortimer, Xenon's President and Chief Financial Officer. Following this introduction, Simon will give an overview of Xenon's clinical programs, and then Ian will review our financial results. After that, we will open up the call to your questions.

Please be advised that during this call, we will make a number of statements that are forward-looking, including statements regarding the timing of and results from clinical trials and preclinical development activities, including those related to our proprietary products and partnered product candidates; the potential efficacy, safety profile, future development plans, addressable market, regulatory success and commercial potential of XEN496, XEN1101, XEN007 and other proprietary and partnered product candidates; the anticipated timing of IND or IND equivalent submissions and the initiation of future clinical trials for XEN496, XEN1101, XEN007 and other proprietary products and those related to NBI-921352, FX301 and other partnered candidates; the efficacy of our clinical trial designs; our ability to successfully develop and achieve milestones in the XEN496, XEN1101, XEN007 and other proprietary development programs; the timing and

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.